These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18983218)

  • 1. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality.
    Liberopoulos EN; Florentin M; Mikhailidis DP; Elisaf MS
    Expert Opin Drug Saf; 2008 Nov; 7(6):717-25. PubMed ID: 18983218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry.
    Gaisenok O; Martsevich S; Tripkosh S; Lukina Y
    Rev Port Cardiol; 2015 Feb; 34(2):111-6. PubMed ID: 25660463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin discontinuation in high-risk patients: a systematic review of the evidence.
    Gomez Sandoval YH; Braganza MV; Daskalopoulou SS
    Curr Pharm Des; 2011 Nov; 17(33):3669-89. PubMed ID: 22074437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-adherence to statin therapy: a major challenge for preventive cardiology.
    Bates TR; Connaughton VM; Watts GF
    Expert Opin Pharmacother; 2009 Dec; 10(18):2973-85. PubMed ID: 19954271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk.
    Nieuwkerk PT; Nierman MC; Vissers MN; Locadia M; Greggers-Peusch P; Knape LP; Kastelein JJ; Sprangers MA; de Haes HC; Stroes ES
    Am J Cardiol; 2012 Sep; 110(5):666-72. PubMed ID: 22621795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering therapy in high-risk persons.
    Aronow WS
    Compr Ther; 2006; 32(2):68-73. PubMed ID: 16845146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease.
    Levy DR; Pearson TA
    Clin Cardiol; 2005 Jul; 28(7):317-20. PubMed ID: 16075823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
    Go AS; Fan D; Sung SH; Inveiss AI; Romo-LeTourneau V; Mallya UG; Boklage S; Lo JC
    Am Heart J; 2017 Dec; 194():25-38. PubMed ID: 29223433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
    Simonyi G
    Orv Hetil; 2014 Apr; 155(17):669-75. PubMed ID: 24755449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
    Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
    JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
    Lee VW; Ho IC; Chan WS; Tam KY; Lee KK
    Am J Cardiovasc Drugs; 2008; 8(3):199-205. PubMed ID: 18533740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not getting to goal: the clinical costs of noncompliance.
    Ansell BJ
    J Manag Care Pharm; 2008 Jul; 14(6 Suppl B):9-15. PubMed ID: 18693783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics.
    Shepherd J
    Atheroscler Suppl; 2007 Aug; 8(2):9-12. PubMed ID: 17586101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care.
    Guglielmi V; Bellia A; Pecchioli S; Della-Morte D; Parretti D; Cricelli I; Medea G; Sbraccia P; Lauro D; Cricelli C; Lapi F
    Atherosclerosis; 2017 Aug; 263():36-41. PubMed ID: 28599257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.